Actions of the clinical vaccination company Novavax (NASDAQ: NVAX) They fell more than 69% in the pre-market market today in response to the failure of the company's respiratory syncytial virus (RSV) in pregnant women. The vaccine, called ResVax, could not protect babies through maternal immunization against the medically significant RSV infection: the main objective of the study.
A positive fact was that the company reported that the data seems to indicate that ResVax helps with some of the most serious consequences of RSV infection, such as hospitalization and severe hypoxemia. Investments, however, have clearly focused on the disappointing result of the study.
This last clinical failure can simply erase billions of dollars in future sales outside the table. ResVax, after all, was projected at $ 668 million in sales until 2024 as an autonomous product. And that figure was expected for the globe to $ 2.6 billion per year, if the company could successfully combine this RSV candidate with its experimental influenza vaccine, according to a EvaluatePharma report.
In spite of this lack of delayed stage, Novavax said that it plans to meet with the American regulators and European to review the data to discuss a potential way for the approval. Given the great unmet medical need presented by the favorable results of RSV and ResVax over these other key metrics, there is an external possibility that regulators can give their blessing. No other candidate for RSV demonstrated a leap of effectiveness, in the end.
But an approval in any territory is an extreme and long shot according to these results. Therefore, with two late phase failures for your RSV program now registered, investors should probably focus their attention directly on the company's flu vaccine pipeline.
George Budwell has no position in any of the mentioned stocks. Motley Fool has no position in any of the mentioned stocks. Motley Fool has a disclosure policy.
The actions of Novavax Inc. They were traded at $ 0.70 per share on Thursday afternoon, with a decrease of $ 1.43 (-67.14%). The following year, the NVAX decreased by -61.96%, compared to an increase of 11.58% in the S & P 500 benchmark during the same period.
NVAX currently has a POWR rating for StockNews.com C (neutral), and is ranked # 88 of 315 actions in the Biotech category.
This article brings you courtesy of The Motley Fool.